Source: Annual Congress 2008 - Inflammatory biomarkers
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
F. L. Dente, L. Melosini, L. Malagrinò, A. Di Franco, F. Costa, F. Novelli, M. Latorre, P. Paggiaro (Pisa, Italy). Relationship between asthma control test (ACT) and clinical, functional and inflammatory markers in treated and non treated asthmatics. Eur Respir J 2008; 32: Suppl. 52, 1112

Member's Comments

No comment yet.

Related content which might interest you: Assessing the relative contribution of the asthma control testÔ (ACT) and spirometry in predicting asthma control Source: Eur Respir J 2004; 24: Suppl. 48, 472s Year: 2004 A comparison of clinical characteristics between cough variant asthma (CVA) and bronchial asthma (BA) in adult patients Source: Annual Congress 2010 - Asthma aspect of diagnosis and criteria for follow-up Year: 2010 Results of the correlation of asthma control test (ACT) with demographic, functional and therapeutic parameters Source: Eur Respir J 2006; 28: Suppl. 50, 208s Year: 2006 Study on levels of high sensitivity C reactive protein in asthmatic patients during exacerbation and remission and its correlation with pulmonary function Source: Annual Congress 2007 - Mechanisms of airway inflammation Year: 2007 Responsiveness of the asthma control test (ACT) to changes in specialists ratings of asthma control and FEV1 Source: Eur Respir J 2004; 24: Suppl. 48, 85s Year: 2004 Applicability of the asthma control test (ACT) in elderly asthmatics Source: Annual Congress 2008 - Basic science in asthma and COPD Year: 2008 Comparison of the asthma control test and % predicted FEV1 in relation to correlation with physicians assessment of asthma control and treatment decisions Source: Annual Congress 2011 - Update on monitoring airway diseases Year: 2011 Managing asthma patients: which outcomes matter? Source: Eur Respir Rev 2008; 17: 53-61 Year: 2008 The effects of rhinitis and smoking on evaluating the asthma control with asthma control test (ACT), FEV1 and FeNO Source: Annual Congress 2008 - Understanding airway inflammation Year: 2008 Relationship between salivary markers of oxidative stress (OS) and different levels of control of bronchial asthma (BA). Source: International Congress 2019 – Evaluation of basic science in airway diseases Year: 2019 Clinical, inflammaory and functional analysis before, during and after treatment with Omalizumabe in patients with difficulty control asthma. Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017 Relationship between COPD assessment test (CAT) and declines of lung function in COPD patients Source: Annual Congress 2012 - COPD: epidemiology and varia Year: 2012 Models of asthma employing ovalbumin in rats and mice: similarities and differences compared with patient asthma Source: Annual Congress 2005 - PG11 - Experimental models for COPD and asthma Year: 2005 Long-term efficacy of omalizumab (OMA) for patients with severe allergic asthma (SAA). Clinical assessment and relationship to serum IgE concentrations Source: International Congress 2015 – The immunology of allergic airway disease Year: 2015 Comparative characteristics of regulatory T cells populations between patients with bronchial asthma (BA) and COPD Source: Annual Congress 2011 - T-cell subsets Year: 2011 The effect of statin usage on airway inflammatiory cells and markers, and clinical indices in asthmatic patients Source: Annual Congress 2011 - Asthma management and response Year: 2011 Budesonid/formoterol easyhaler: clinical efficiency and adherence to treatment in patients with partly controlled bronchial asthma (BA). Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017 The correlation between expression of selected inflammatory mediators in induced sputum and respiratory tests in asthma and COPD Source: International Congress 2015 – Systemic and airway biomarkers Year: 2015 Small airways function: evaluation in a population of adult patients with severe asthma and potential use as a response biomarker for anti-IL5 therapy Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020 Discrepancy of non-invasive inflammatory markers and lung function tests to current level of clinical control in childhood asthma Source: Annual Congress 2009 - FeNO and other biomarkers in childhood asthma Year: 2009